Buying guide
LocusBot vs Hugo RAS in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
On DEPLOY's record, LocusBot has more verified real-world deployments (11 versus 4) than Hugo RAS as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source.
- LocusBot has more capabilities independently verified as autonomous (1 vs 0).
- LocusBot has more verified real-world deployments (11 vs 4).
| Attribute | ||
|---|---|---|
| Manufacturer | Locus Robotics | Medtronic |
| Form factor | amr | surgical |
| Maturity | commercial | commercial |
| Autonomy | ✓ 1 verified autonomous | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | Not announced | Not announced |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 11 | 4 |
| Privacy practices | — | — |
| Sources on file | 26 | 18 |
Track this matchup
Get told the moment LocusBot or Hugo RAS changes. Verified changes only, the second they are real. No press-release noise.
LocusBot
Hugo RAS
Editorial summaries
LocusBot
Locus Robotics (Wilmington, Massachusetts) makes the LocusBot, a collaborative goods-to-person picking AMR that works alongside human pickers, delivered on a Robots-as-a-Service subscription via the LocusONE platform. There is no consumer price: it is a B2B warehouse-automation subscription, not a robot sold to consumers. It is at commercial maturity, operating across 150-plus customers and 350-plus sites in 20 countries, having surpassed 6 billion cumulative picks by October 2025 (DHL Supply Chain a marquee customer), and it raised a $117 million Series F at a roughly $2 billion valuation in 2022 (a point-in-time figure).
In April 2026 it launched Locus Array, a mobile-manipulation system extending from collaborative picking toward fully autonomous fulfillment. The pick-count and fleet figures are company-reported, and the ~$2 billion valuation is a November-2022 datapoint. Locus anchors the RaaS / multi-customer end of the warehouse-AMR business-model spectrum.
Hugo RAS
Medtronic's Hugo RAS is a modular, multi-port teleoperated robotic-assisted-surgery system and the main commercial competitor to Intuitive's da Vinci. It is CE-marked in Europe (urology and gynecology, October 2021) and US FDA-cleared for urology only (December 2025: prostatectomy, nephrectomy, cystectomy); US general-surgery and gynecology indications are planned but not yet cleared.
It is teleoperated with no shipped intraoperative AI. Medtronic does not disclose a Hugo installed-base count, so DEPLOY records honest absence rather than an invented number. It is enterprise B2B equipment; there is no consumer price.
Common questions
How do LocusBot and Hugo RAS differ?
What is the difference between LocusBot and Hugo RAS?
Is LocusBot or Hugo RAS more autonomous?
Recent coverage
- Medtronic to unveil Touch Surgery Aide compute platform at SRS 2026Hugo RAS · Ben Smith, Deploy Editor · 2026-07-21
- Medtronic adds real-time AI to Hugo robotHugo RAS · MedTech Dive · 2026-07-21
- Locus Robotics acquires Nexera Robotics for grasping technologyLocusBot · Ben Smith, Deploy Editor · 2026-05-19
- Locus Robotics acquires Nexera Robotics advancing mobile manipulationLocusBot · Ben Smith, Deploy Editor · 2026-05-19
Related comparisons
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.

